关于公司
Galectin Therapeutics looks to help patients with NASH cirrhosis and cancer. Galectin’s lead drug (GR-MD-02, or belapectin) is a galectin-3 inhibitor.
US
未知
未验证公司
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论
Galectin Therapeutics looks to help patients with NASH cirrhosis and cancer. Galectin’s lead drug (GR-MD-02, or belapectin) is a galectin-3 inhibitor.